Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update

Arvinas, Inc. (NASDAQ:ARVN – Get Rating) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 5,070,000 shares, a growth of 6.5% from the February 13th total of 4,760,000 shares. Approximately 11.1% of the shares of the stock are short sold. Based on an average trading volume of 491,100 shares, the short-interest ratio is currently 10.3 days.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ARVN shares. The Goldman Sachs Group restated a “buy” rating and issued a $81.00 target price on shares of Arvinas in a report on Monday, November 28th. Barclays cut their target price on shares of Arvinas from $90.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, November 23rd. Wells Fargo & Company lowered Arvinas from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $83.00 to $49.00 in a research note on Monday, January 2nd. Credit Suisse Group dropped their price target on Arvinas from $81.00 to $61.00 and set an “outperform” rating for the company in a research note on Friday, February 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Arvinas in a research note on Friday, February 24th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.44.

Insider Buying and Selling at Arvinas

In other Arvinas news, CEO John G. Houston sold 5,878 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a total transaction of $173,577.34. Following the transaction, the chief executive officer now directly owns 917,427 shares in the company, valued at $27,091,619.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Arvinas news, CEO John G. Houston sold 5,878 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a total transaction of $173,577.34. Following the transaction, the chief executive officer now directly owns 917,427 shares in the company, valued at $27,091,619.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean A. Cassidy sold 1,745 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a total transaction of $51,529.85. Following the transaction, the chief financial officer now owns 183,618 shares in the company, valued at $5,422,239.54. The disclosure for this sale can be found here. Insiders have sold 8,674 shares of company stock worth $256,143 over the last ninety days. Insiders own 2.78% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Several large investors have recently bought and sold shares of ARVN. Norges Bank bought a new stake in Arvinas in the 4th quarter worth about $24,007,000. Avidity Partners Management LP increased its holdings in Arvinas by 14.0% in the 4th quarter. Avidity Partners Management LP now owns 4,950,000 shares of the company’s stock worth $169,340,000 after buying an additional 606,500 shares in the last quarter. Finepoint Capital LP bought a new stake in Arvinas in the 3rd quarter worth about $17,752,000. Brown Advisory Inc. bought a new stake in Arvinas in the 2nd quarter worth about $12,133,000. Finally, Eventide Asset Management LLC bought a new stake in Arvinas in the 3rd quarter worth about $12,524,000. 92.03% of the stock is currently owned by institutional investors.

Arvinas Price Performance

ARVN opened at $29.54 on Thursday. The stock has a 50-day moving average price of $32.47 and a 200-day moving average price of $39.01. The firm has a market cap of $1.57 billion, a PE ratio of -5.55 and a beta of 1.78. Arvinas has a 1 year low of $26.57 and a 1 year high of $75.39.

Arvinas (NASDAQ:ARVN – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.46). The company had revenue of $38.00 million during the quarter, compared to analysts’ expectations of $35.32 million. Arvinas had a negative return on equity of 43.79% and a negative net margin of 228.19%. Arvinas’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.00) EPS. As a group, sell-side analysts anticipate that Arvinas will post -6.01 EPS for the current year.

About Arvinas

(Get Rating)

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.